well
@col69Stop being a bully please
It would be much appreciated
Below is a graphic of how the voting went
There was approximately 55-58% of share holder base that voted yes/no on the remuneration question
View attachment 4522741It is obviously the institutions holding around 51.4% (209,299,625 shares) of the company who voted
for the resolutions
The balance is made up of share registry is comprised of the following
general public 42.3% (172,465,186 shares) , WHO VERY RARELY BOTHER TO VOTE UNLESS LOBBIED.
individual insiders 3.4% (13,909,225 shares) , WHO WOULD VOTE FOR THE RESOLUTIONS
private companies 2.5% (10,321,580 shares) and WHO WOULD MOST PROBABLY VOTE. I CERTAINLY DID
government 0.4% (1,448,798 shares). WHO MOST PROBABLY VOTE FOR THE RESOLUTIONS OR NOT GIVE A STUFF
"I am guessing the fan club will vote yes yet again for their remuneration at the 2022 AGM"
SO BASED ON YOUR ABOVE STATEMENT WOULD YOU BE REFERRING TO THE INSTITUTIONS WHO VOTED IN FAVOUR OF ALL THE RESOLUTIONS LAST YEARor most of the general public that did not bother to voteit's plain to see....... it was not the retail shareholders...........who most probably
are not proactive (in other words do not give a rats)
In regards to your quote
expecting DEP results by 30 June as touted by the company themselvesplease do not make up things to suit your agenda BELOW IS A DIRECT QUOTE FROM JACKIE FAIRLEY IN REGARDS TO READ OUT OF THREE DEP DRUGS IN PHASE 2 TRIALS AND COMPLETION WORD FOR WORD
AND I QUOTE
"Our
expectations in terms of timing of these
our
expectations is for all three of these phase *3 products to be completing and reading out in
calendar year 2022*And I wouldexpect that the first half would include dep docetaxel and the prostate component of dep cabazitaxel*and I am going to talk about ovarian and oesophageal cancer in dep cabazitaxel in a moment because we've seen some excellent results there and
would be likely to be in the second half
and dep irinotecan
more likely to be in the second half of calendar 2022"
Unquote
So never has she stated the words willNevertheless I hope readouts will occur around this time frame
On another note
I was very happy to see the progression of all of the AZD0466 trials. I understand there are is
now recruiting in
10 additional sites for all the trials and an
expansion of additional 15 locations (formally 10 now expanded to 25) in the NHL trial and an additional 3 locations in the AZD0466 combination studyTHIS BRINGS ONLINE AN ADDITIONAL 13 LOCATIONS FOR THE 2 TRIALS SO FARMy understanding of timelines so far
Dep Docetaxel
Dep Cabazitaxel
Dep Irinotecan
Completion and data readout this calendar year
AZD0466 entering phase 2 this calendar year (and subsequent milestone payments)
Dep Gembitabine entering FIHT imminently
Radiotherapeutic partnership signed with big pharma this calendar year
TGA approves Viraleze into Australia imminently
Starpharma sacks Mundipharma or something massive is planned in marketing Vivagel. Mundipharma go all out and spend a few million promoting product this calendar year
FDA NDA approval is granted finally this calendar year or the study that was put on hold is initiated in the USA
Another indication for AZD0466 is put into clinical trials sometime this calendar year
An ADC trial or multiple trials in FIHT's are initiated this calendar year
Several more new partnerships are announced with big pharma this calendar year
There is a lot more.......
Oh and finally the share price goes above it's historical high
The above in reference to timelines is my opinion
DYOR
